Involvement of p21(Waf1) in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells

Anticancer Research

Volumn 20, Issue 1 A, 2000, Pages 103-111

  Fang, Min ^a   Liu, Bolin ^a   Schmidt, Mathias ^a   Lu, Yang ^a   Mendelsohn, John ^a   Fan, Zhen ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL EXTRACT; EPIDERMAL GROWTH FACTOR; PACLITAXEL; PROTEIN KINASE; PROTEIN P21; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; HYBRID PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; ADENOCARCINOMA; BREAST TUMOR; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; NEOPLASM PROTEINS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PACLITAXEL; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033624845     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rowinsky EK: Paclitaxel pharmacology and other tumor types. Semin Oncol 24 (suppl 19): 1-12, 1997.
2. Schiff PB and Horwitz SB: Taxol stabilizes microtuhules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
3. Horwitz SB: Mechanism of action of Taxol. Trends Pharmacol Sci 13: 134-136, 1992.
4. Taketani Y and Oka T: Biological action of epidermal growth factor and its functional receptors in normal mammary epithelial cells. Proc Natl Acad Sci USA 80: 2647-2650, 1983.
5. Carpenter G and Cohen S: Epidermal growth factor. Annu Rev Biochem 48: 193-216, 1979.
6. Gill GN and Lazar CS: Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 293: 305-307, 1981.
7. Filmus J, Pollak MN, Cailleau R, and Buick RN: MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128: 898-905, 1985.
8. Gross ME, Zorbas MA, Danels YJ, Garcia R, Gallick GE, Olive M, Brattain MG, Boman BM, and Yeoman LC: Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 51: 1452-1459, 1991.
9. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol 131: 235-242, 1995.
10. WAF1/Cip1 and alter cell cycle control in squamous carcinoma cells. Oncogene 12: 2369-2376, 1996.
11. WAF1. Anticancer Res 17: 2627-2633, 1997.
12. WAF1/Cip1 expression and growth inhibition of A431 cells. Biochem Biophys Res Commun 250: 430-435, 1998.
13. Bromberg JF, Fan Z, Brown C, Mendelsohn J, and Darnell JJ: Epidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ 9: 505-512, 1998.
14. Donaldson KL, Goolsby GL, Kiener PA, and Wahl AF: Activation of p34cdc2 coincident with Taxol-induced apoptosis. Cell Growth Differ 5: 1041-1050, 1994.
15. Trielli MO, Andreassen PR, Lacroix FB, and Margolis RL: Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. J Cell Biol 135: 689-700, 1996.
16. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501, 1998.
17. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, and O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654, 1995.
18. Fan S, Chang JK, Smith ML, Duba D, Fornace AJ, and O'Connor PM: Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14: 2127-2136, 1997.
19. Deng C, Zhang P, Harper JW, Elledge SJ, and Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684, 1995.
20. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P. Glover T, Collins FS, Wetson A, Modali R, Harris CC, and Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1998.
21. Reiss M, Brash DE, Munoz-Antonia T, Simon JA, Ziegler A, Vellucci VF, and Zhou ZL: Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol Res 4: 349-357, 1992.
22. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, and Koeffler HP: Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 9: 1899-1906, 1994.
23. Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503-508, 1990.
24. Doree M: Control of M-phase by maturation-promoting factor. Curr Opin Cell Biol 2: 269-273, 1990.
25. WAF1 and p53 requires c-raf-1. Cancer Res 55: 4623-4626, 1995.
26. Barboule N, Chadebech P, Baldin V, Vidal S, and Valette A: Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 15: 2867-2875, 1997.
27. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
28. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, and Wei N: Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6: 387-400, 1995.
29. Medema RH, Klompmaker R, Smits VA, and Rijksen G: p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 16: 431-441, 1998.
30. Cayrol C, Knibiehler M, and Ducommun B: p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16: 311-320, 1998.
31. Cip1/Waf1 at both the G1/S and the G2/M cell cycletransitions: pRB is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
32. Dulic V, Stein GH, Far DF, and Reed SI: Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Biol 18: 546-557, 1998.